These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 16990605)
1. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Astermark J; Donfield SM; DiMichele DM; Gringeri A; Gilbert SA; Waters J; Berntorp E; Blood; 2007 Jan; 109(2):546-51. PubMed ID: 16990605 [TBL] [Abstract][Full Text] [Related]
2. Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. Steen Carlsson K; Astermark J; Donfield S; Berntorp E Thromb Haemost; 2008 Jun; 99(6):1060-7. PubMed ID: 18521509 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic decision-making in inhibitor patients. Allen G; Aledort L Am J Hematol; 2006 Jan; 81(1):71-2. PubMed ID: 16369965 [TBL] [Abstract][Full Text] [Related]
4. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Hayashi T; Tanaka I; Shima M; Yoshida K; Fukuda K; Sakurai Y; Matsumoto T; Giddings JC; Yoshioka A Haemophilia; 2004 Jul; 10(4):397-400. PubMed ID: 15230956 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Zhou ZY; Hay JW Clin Ther; 2012 Feb; 34(2):434-45. PubMed ID: 22285208 [TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Joshi AV; Stephens JM; Munro V; Mathew P; Botteman MF Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427 [TBL] [Abstract][Full Text] [Related]
7. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Young G; Shafer FE; Rojas P; Seremetis S Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834 [TBL] [Abstract][Full Text] [Related]
8. Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors. Tjønnfjord GE; Holme PA Vasc Health Risk Manag; 2007; 3(4):527-31. PubMed ID: 17969383 [TBL] [Abstract][Full Text] [Related]
9. From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitors. Gomperts ED; Astermark J; Gringeri A; Teitel J Blood Rev; 2008 Feb; 22 Suppl 1():S1-11. PubMed ID: 18485996 [TBL] [Abstract][Full Text] [Related]
10. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: different approaches for different clinical situations. Jiménez-Yuste V; Alvarez MT; Martín-Salces M; Quintana M; Rodriguez-Merchan C; Lopez-Cabarcos C; Velasco F; Hernández-Navarro F Haemophilia; 2009 Jan; 15(1):203-9. PubMed ID: 19149850 [TBL] [Abstract][Full Text] [Related]
11. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. Negrier C; Goudemand J; Sultan Y; Bertrand M; Rothschild C; Lauroua P Thromb Haemost; 1997 Jun; 77(6):1113-9. PubMed ID: 9241742 [TBL] [Abstract][Full Text] [Related]
12. FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French 'FEIBA dans l'hémophilie A acquise' (FEIBHAC) registry. Borg JY; Négrier C; Durieu I; Dolimier E; Masquelier AM; Lévesque H; Haemophilia; 2015 May; 21(3):330-337. PubMed ID: 25359571 [TBL] [Abstract][Full Text] [Related]
13. Current opinion on inhibitor treatment options. Mathew P Semin Hematol; 2006 Apr; 43(2 Suppl 4):S8-13. PubMed ID: 16690374 [TBL] [Abstract][Full Text] [Related]
14. Systematic monitoring of hemostatic management in hemophilia A patients with inhibitor in the perioperative period using rotational thromboelastometry. Furukawa S; Nogami K; Ogiwara K; Yada K; Minami H; Shima M J Thromb Haemost; 2015 Jul; 13(7):1279-84. PubMed ID: 25903848 [TBL] [Abstract][Full Text] [Related]
15. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Franchini M; Coppola A; Tagliaferri A; Lippi G Semin Thromb Hemost; 2013 Oct; 39(7):772-8. PubMed ID: 24014071 [TBL] [Abstract][Full Text] [Related]
16. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. Holmberg HL; Lauritzen B; Tranholm M; Ezban M J Thromb Haemost; 2009 Sep; 7(9):1517-22. PubMed ID: 19566792 [TBL] [Abstract][Full Text] [Related]
17. Prophylaxis in haemophilia with inhibitors: update from international experience. Carcao M; Lambert T Haemophilia; 2010 Mar; 16 Suppl 2():16-23. PubMed ID: 20132334 [TBL] [Abstract][Full Text] [Related]
18. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience. Holme PA; Glomstein A; Grønhaug S; Tjønnfjord GE Haemophilia; 2009 May; 15(3):727-32. PubMed ID: 19320748 [TBL] [Abstract][Full Text] [Related]
19. Acquired haemophilia: management of bleeds and immune therapy to eradicate autoantibodies. Holme PA; Brosstad F; Tjønnfjord GE Haemophilia; 2005 Sep; 11(5):510-5. PubMed ID: 16128896 [TBL] [Abstract][Full Text] [Related]
20. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Key NS; Aledort LM; Beardsley D; Cooper HA; Davignon G; Ewenstein BM; Gilchrist GS; Gill JC; Glader B; Hoots WK; Kisker CT; Lusher JM; Rosenfield CG; Shapiro AD; Smith H; Taft E Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]